InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
T+90 hit rate
50%
T+90 mean return
-4.7%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by PAKOLA STEVE, Directeur Médical. Officer active across 1 company, notably REGENXBIO Inc.. In total, 10 reports have been recorded. Breakdown: 0 buy · 1 sell. Total volume traded: €26k. History available since 1 January 2022. The latest transaction was disclosed on 2 July 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations10 total
2,161 shares@ US$7.860.0022% mcap2.1% of flowCommon StockSEC:0001700659-26-000014:0
2,161 shares@ US$13.640.0039% mcap3.6% of flowCommon StockSEC:0001700659-26-000014:1
5,263 shares@ US$8.076.0% of flowCommon StockSEC:0001562180-25-003009:0
13,891 shares@ US$7.7315.2% of flowCommon StockSEC:0001562180-25-000190:0
58,386 shares0Common StockSEC:0001562180-24-006017:0
12,878 shares@ US$22.2538.7% of flowCommon StockSEC:0001562180-24-002430:0
10,385 shares@ US$17.9524.7% of flowCommon StockSEC:0001562180-24-000252:0
1,837 shares@ US$22.685.7% of flowCommon StockSEC:0001562180-23-000222:0
1,152 shares@ US$32.704.9% of flowCommon StockSEC:0001562180-22-000159
1,152 shares@ US$32.700.011% mcap50.0% of flowCommon StockSEC:0001562180-22-000159:0
10 of 10 declarations
About PAKOLA STEVE
Steve Pakola is the Chief Medical Officer at Regenxbio Inc. He oversees the company's medical initiatives, including product development and clinical trials. With a strong medical background, he plays a key role in the strategic direction of research and development programs. His expertise contributes to innovation and improved patient outcomes.
